What is the Apellis Pharmaceuticals Inc (APLS) price today?

The price of Apellis Pharmaceuticals Inc (APLS) today is $40.9. This value reflects the latest market rate available on Pluang. Check the asset page for additional details such as 24-hour change, market trends, and trading volume.

What are the trading hours of US Stocks?

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.

Do I get a dividend from investing in US Stocks?

Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.

What is the fee for each transaction?

Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.

Trade on Pluang

One platform for all markets

Download

Investment

Features

Fees Safety

Academy

Pluang+

Home/Explore/US Market Price/Stocks/APLS

Buy & Sell Apellis Pharmaceuticals Inc (APLS) – Apellis Pharmaceuticals Inc Price Today

Overview Financials Technicals Analysis Corp Action About

24H

YTD

Aura AI Summary

Apellis Pharmaceuticals (APLS) trades at $40.90, just below the $41.00 acquisition price offered by Biogen, following a 136% surge on the deal announcement. The stock is at a 52-week high with strong technical momentum. Fundamentally, the company shows robust revenue growth to $1.0B in 2025 and high gross margins of 89.8%, though net margins remain thin at 2.2%. Recent earnings have been mixed, with beats in Q2 and Q3 2025 but a miss in Q4.

The investment thesis is now dominated by the pending $5.6B acquisition by Biogen at $41 per share plus contingent value rights, offering a clear near-term exit. The primary risk is deal completion, with multiple law firms investigating the fairness of the transaction. Analyst sentiment is positive, with a 71% buy rating, but the consensus price target of $34.09 sits below the current offer, suggesting the market is pricing in deal certainty.

Read full analysis

Key Stats

Market Cap
$5.23B
Sector
Health
3M Drawdown
-27.76%
Enterprise Value
$5.24B
Dividend Yield
-
Typical Hold Time
2 days

$40.9

52W Low: $16.36

15 May 2025

52W High: $40.9

17 Apr 2026

Apellis Pharmaceuticals Inc (APLS) is currently valued at a market capitalization of $5.23B, with an enterprise value of $5.24B. Over the past 52 weeks, Apellis Pharmaceuticals Inc has traded between a low of $16.36 and a high of $40.9, highlighting its annual price range. Over the past three months, Apellis Pharmaceuticals Inc has recorded a drawdown of -27.76%, reflecting recent price volatility. On average, investors hold Apellis Pharmaceuticals Inc for approximately 2 days, indicating typical investor behavior on the platform.

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is a biopharmaceutical company focused on complement science. It develops therapies for serious diseases, including the first-ever treatment for geographic atrophy, a leading cause of blindness.

Technical Indicators

Overall Summary

Bearish (12)Neutral (7)Bullish (4)

News

Benzinga3 mon ago

TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

Benzinga3 mon ago

Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday?

Globe Newswire3 mon ago

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Globe Newswire5 mon ago

Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight

Globe Newswire5 mon ago

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

People also bought

US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

Market Cap
$5.23B
Sector
Health
3M Drawdown
-27.76%
Enterprise Value
$5.24B
Dividend Yield
-
Typical Hold Time
2 days

$40.9

52W Low: $16.36

15 May 2025

52W High: $40.9

17 Apr 2026

Let’s invest in this asset by signing up or download!

Buy & Sell Apellis Pharmaceuticals Inc (APLS) – Apellis Pharmaceuticals Inc Price Today

Aura AI Summary

Key Stats

About Apellis Pharmaceuticals Inc

People also bought

Key Stats

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store